IUG.L

Intelligent Ultrasound
Intelligent Ultrasnd - Result of General Meeting
15th October 2024, 10:59
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2762I
Intelligent Ultrasound Group PLC
15 October 2024
 

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Group" or the "Company")

 

Result of General Meeting

Shareholders approve capital reduction

 

 

Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound simulation and education company, announces that at the general meeting held on 15th October 2024, shareholders approved the capital reduction, the preliminary step to provide the distributable reserves required to return capital to shareholders following the sale of the Clinical AI Business to GE HealthCare for £40.5 million.

 

Results show that 99.99% of the shares voted (representing approximately 60% of the total shares outstanding) were in favour, with 0.01% against.

 

The capital reduction is expected to be confirmed by Court Order on 18th November, after which further details on the Company's plans for its Simulation Business will be announced.

 

For further information, please contact:

 

 

Intelligent Ultrasound Group plc

www.intelligentultrasound.com

Stuart Gall, CEO

Tel: +44 (0)29 2075 6534

Helen Jones, CFO

 


 

Cavendish Capital Markets Limited

(Nominated advisor and broker)

 

 

Giles Balleny / Dan Hodkinson (Corporate Finance)

Nigel Birks (Life Sciences Specialist Sales)

Dale Bellis (Sales)

Tel: +44 (0)20 7397 8900

 



Cardew Group - PR Advisors

Intelligentultrasound@cardewgroup.com 

Allison Connolly

Emma Pascoe-Watson

Jessica Pilling

Tel: +44 (0)7587 453955

Tel: +44 (0)7774 620415

Tel: +44 (0)7918 584573

 

 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading ultrasound simulation and education companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market. The company's main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator, the new BabyWorks Neonate and Paediatric training simulator and NeedleTrainer, which teaches real-time ultrasound-guided needling. To date over 1,800 simulators have been sold to over 800 medical institutions around the world.

 

 

www.intelligentultrasound.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMBGBDGLUBDGSU]]>
TwitterFacebookLinkedIn